دورية أكاديمية
أعرض في EDS

Complexity of Medication Regimens for Children With Neurological Impairment.

التفاصيل البيبلوغرافية
العنوان: Complexity of Medication Regimens for Children With Neurological Impairment.
المؤلفون: Feinstein JA; Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado and Children's Hospital Colorado, Aurora.; Department of Pediatrics, University of Colorado, Aurora., Friedman H; Pediatric Residency Program, University of Colorado, Aurora., Orth LE; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora., Feudtner C; Division of General Pediatrics, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Kempe A; Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado and Children's Hospital Colorado, Aurora.; Department of Pediatrics, University of Colorado, Aurora., Samay S; Research Informatics, Analytics Resource Center, Children's Hospital Colorado, Aurora., Blackmer AB; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora.
المصدر: JAMA network open [JAMA Netw Open] 2021 Aug 02; Vol. 4 (8), pp. e2122818. Date of Electronic Publication: 2021 Aug 02.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Chicago, IL : American Medical Association, [2018]-
مواضيع طبية MeSH: Drug Administration Schedule*, Chronic Disease/*drug therapy , Medication Adherence/*statistics & numerical data , Nervous System Diseases/*drug therapy, Adolescent ; Child ; Child, Preschool ; Cross-Sectional Studies ; Female ; Humans ; Infant ; Male ; United States
مستخلص: Importance: Parents of children with severe neurological impairment (SNI) manage complex medication regimens (CMRs) at home, and clinicians can help support parents and simplify CMRs.
Objective: To measure the complexity and potentially modifiable aspects of CMRs using the Medication Regimen Complexity Index (MRCI) and to examine the association between MRCI scores and subsequent acute visits.
Design, Setting, and Participants: This cross-sectional study was conducted between April 1, 2019, and December 31, 2020, at a single-center, large, hospital-based, complex care clinic. Participants were children with SNI aged 1 to 18 years and 5 or more prescribed medications.
Exposure: Home medication regimen complexity was assessed using MRCI scores. The total MRCI score is composed of 3 subscores (dosage form, dose frequency, and specialized instructions).
Main Outcomes and Measures: Patient-level counts of subscore characteristics and additional safety variables (total doses per day, high-alert medications, and potential drug-drug interactions) were analyzed by MRCI score groups (low, medium, and high score tertiles). Associations between MRCI score groups and acute visits were tested using Poisson regression, adjusted for age, complex chronic conditions, and recent health care use.
Results: Of 123 patients, 73 (59.3%) were male with a median (interquartile range [IQR]) age of 9 (5-13) years. The median (IQR) MRCI scores were 46 (35-61 [range, 8-139]) overall, 29 (24-35) for the low MRCI group, 46 (42-50) for the medium MRCI group, and 69 (61-78) for the high MRCI group. The median (IQR) counts for the subscores were 6 (4-7) dosage forms per patient, 7 (5-9) dose frequencies per patient, and 5 (4-8) instructions per patient, with counts increasing significantly across higher MRCI groups. Similar trends occurred for total daily doses (median [IQR], 31 [20-45] doses), high-alert medications (median [IQR], 3 [1-5] medications), and potential drug-drug interactions (median [IQR], 3 [0-6] interactions). Incidence rate ratios of 30-day acute visits were 1.26 times greater (95% CI, 0.57-2.78) in the medium MRCI group vs the low MRCI group and 2.42 times greater (95% CI, 1.10-5.35) in the high MRCI group vs the low MRCI group.
Conclusions and Relevance: Higher MRCI scores were associated with multiple dose frequencies, complicated by different dosage forms and instructions, and associated with subsequent acute visits. These findings suggest that clinical interventions to manage CMRs could target various aspects of these regimens, such as the simplification of dosing schedules.
References: JAMA Netw Open. 2020 Dec 1;3(12):e2029082. (PMID: 33306117)
Pediatrics. 2014 Aug;134(2):338-60. (PMID: 25022737)
Clin Ther. 2013 Apr;35(4):385-398.e1. (PMID: 23541707)
Arch Pediatr Adolesc Med. 2010 Feb;164(2):181-6. (PMID: 20124148)
BMJ Open. 2019 Jan 28;9(1):e020554. (PMID: 30696664)
J Am Pharm Assoc (2003). 2019 May - Jun;59(3):383-389. (PMID: 30954401)
Pediatrics. 2021 Feb;147(2):. (PMID: 33414236)
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72. (PMID: 16381955)
Pharmacotherapy. 2014 Aug;34(8):826-35. (PMID: 24947636)
J Nurs Res. 2015 Sep;23(3):189-96. (PMID: 25723125)
PLoS One. 2018 Nov 29;13(11):e0208047. (PMID: 30496322)
J Hosp Med. 2019 Aug;14(8):506-507. (PMID: 31386617)
Acad Pediatr. 2017 May - Jun;17(4):403-410. (PMID: 28477800)
Ann Pharmacother. 2018 Nov;52(11):1117-1134. (PMID: 29756471)
Ann Pharmacother. 2004 Sep;38(9):1369-76. (PMID: 15266038)
Hosp Pediatr. 2019 Nov;9(11):844-850. (PMID: 31582401)
Pediatrics. 2020 Nov;146(5):. (PMID: 33037121)
Expert Opin Drug Saf. 2013 Nov;12(6):829-40. (PMID: 23984969)
Ment Health Clin. 2020 Jul 2;10(4):207-214. (PMID: 32685331)
BMJ Paediatr Open. 2020 Nov 26;4(1):e000841. (PMID: 33305018)
J Pediatr Pharmacol Ther. 2021;26(1):62-72. (PMID: 33424502)
Lancet. 2007 Oct 20;370(9596):1453-7. (PMID: 18064739)
Pharmacoepidemiol Drug Saf. 2019 Mar;28(3):275-287. (PMID: 30724414)
J Pediatr. 2019 Dec;215:244-251.e1. (PMID: 31604631)
JAMA Pediatr. 2019 Oct 1;173(10):989-991. (PMID: 31424541)
Sr Care Pharm. 2020 Feb 1;35(2):81-84. (PMID: 32085817)
J Pediatr Pharmacol Ther. 2018 May-Jun;23(3):177-191. (PMID: 29970974)
Pharm Pract (Granada). 2015 Oct-Dec;13(4):659. (PMID: 26759621)
J Am Geriatr Soc. 2017 Apr;65(4):747-753. (PMID: 27991653)
Int J Clin Pharm. 2014 Aug;36(4):750-6. (PMID: 24906719)
J Pediatr Pharmacol Ther. 2018 Jan-Feb;23(1):4-17. (PMID: 29491747)
Am J Geriatr Pharmacother. 2012 Aug;10(4):223-9. (PMID: 22749668)
BMC Geriatr. 2017 Oct 10;17(1):230. (PMID: 29017448)
Ann Pharmacother. 2016 Feb;50(2):89-95. (PMID: 26681444)
Clin Interv Aging. 2020 Jun 02;15:797-809. (PMID: 32581521)
Clin Ther. 2014 Nov 1;36(11):1538-1546.e1. (PMID: 25456562)
Ann Pharmacother. 2016 Jul;50(7):534-40. (PMID: 27147704)
Child Care Health Dev. 2017 May;43(3):323-333. (PMID: 27896838)
Pediatrics. 2017 Jul;140(1):. (PMID: 28759396)
J Pediatr. 2008 Feb;152(2):225-31. (PMID: 18206693)
J Patient Saf. 2014 Dec;10(4):186-91. (PMID: 25408236)
Paediatr Child Health. 2019 Aug;24(5):303-305. (PMID: 31379430)
Ann Pharmacother. 2014 Jan;48(1):26-32. (PMID: 24259639)
Pediatrics. 2019 Apr;143(4):. (PMID: 30914443)
JAMA Pediatr. 2018 Jun 1;172(6):596-598. (PMID: 29710063)
Pharmacotherapy. 2019 Jun;39(6):636-644. (PMID: 30508268)
JAMA Pediatr. 2020 Nov 1;174(11):1114-1117. (PMID: 33044500)
معلومات مُعتمدة: K23 HD091295 United States HD NICHD NIH HHS
تواريخ الأحداث: Date Created: 20210826 Date Completed: 20220110 Latest Revision: 20220110
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8391103
DOI: 10.1001/jamanetworkopen.2021.22818
PMID: 34436607
قاعدة البيانات: MEDLINE
الوصف
تدمد:2574-3805
DOI:10.1001/jamanetworkopen.2021.22818